Ipsen マネジメント

マネジメント基準チェック /24

Ipsenの CEO はDavid Loewで、 Jul2020年に任命され、の在任期間は 6.17年です。の年間総報酬は€ 10.42Mで、 9.8%給与と90.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.11%を直接所有しており、その価値は€ 13.78M 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と11.3年です。

主要情報

David Loew

最高経営責任者

€10.4m

報酬総額

CEO給与比率	9.84%
CEO在任期間	6.2yrs
CEOの所有権	0.1%
経営陣の平均在職期間	4.1yrs
取締役会の平均在任期間	11.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Ipsen の収益と比較して、David Loew の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2026	n/a	n/a	€513m
Mar 31 2026	n/a	n/a	€478m
Dec 31 2025	€10m	€1m	€444m
Sep 30 2025	n/a	n/a	€446m
Jun 30 2025	n/a	n/a	€448m
Mar 31 2025	n/a	n/a	€402m
Dec 31 2024	€5m	€1m	€356m
Jun 30 2024	n/a	n/a	€664m
Mar 31 2024	n/a	n/a	€641m
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

報酬と市場: Davidの総報酬 ($USD 12.12M ) は、 German市場 ($USD 6.14M ) の同規模の企業の平均を上回っています。

報酬と収益: Davidの報酬は過去 1 年間で 20% 以上増加しました。

CEO

David Loew (59 yo)

6.2yrs

在職期間

€10,417,318

報酬

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020 and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Loew	MD, CEO & Director	6.2yrs	€10.42m	0.11% € 13.8m
Aymeric Le Chatelier	Executive VP & CFO	11.8yrs	€1.02m	データなし
Pierrick Lefranc	Executive VP & Head of Technical Operations	less than a year	データなし	データなし
Henry Wheeler	Global Vice President of Investor Relations	no data	データなし	データなし
Caroline Sitbon	Executive VP & General Counsel	1yr	データなし	データなし
Sally Bain	Head of Global Media Relations	no data	データなし	データなし
Regis Mulot	Executive VP & Chief Human Resources Officer	8.5yrs	データなし	データなし
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	5.9yrs	データなし	データなし
Mari Scheiffele	Executive VP	4.8yrs	データなし	データなし
Sandra Silvestri	Executive VP & Chief Medical Officer	3.3yrs	データなし	データなし
Christelle Huguet	Executive VP and Head of R&D	3yrs	データなし	データなし
Josep Catlla	Executive VP & Chief Corporate Affairs Officer	2.1yrs	データなし	データなし

4.1yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: I7G0の経営陣は経験豊富であると考えられます ( 4.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
David Loew	MD, CEO & Director	6.3yrs	€10.42m	0.11% € 13.8m
Marc M. de Garidel	Non-Executive Chairman	15.8yrs	€600.00k	0.16% € 21.4m
Margaret Liu	Independent Director	9.3yrs	€170.00k	0.00084% € 109.2k
Michèle Ollier	Director	11.3yrs	€110.95k	0.00061% € 79.3k
Antoine Flochel	Vice Chairman	21.1yrs	€189.32k	0.0037% € 475.6k
Anne Beaufour	Director	21.1yrs	€60.00k	26.61% € 3.5b
Piet Wigerinck	Independent Director	no data	€135.00k	データなし
Carol Xueref	Director	14.3yrs	€170.35k	0.00061% € 79.3k
Philippe Bonhomme	Director	14.7yrs	€155.00k	データなし
Catherine-Annick Bradley	Independent Director	less than a year	データなし	データなし
Laetitia Ducroquet	Employees Representative Director	5.8yrs	データなし	0.0016% € 213.1k
Naomi Binoche	Employee Representative Director	4.3yrs	データなし	0.0042% € 547.1k

11.3yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: I7G0の取締役会は経験豊富で経験豊富です ( 11.3年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/09/09 14:03
終値	2026/09/09 00:00
収益	2026/06/30
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築したご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ipsen S.A. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。27

アナリスト	機関
Richard Silver	Barclays
Charles Pitman	Barclays
Yihan Li	Barclays

Ipsen マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026

Ipsen S.A., Annual General Meeting, May 13, 2026

Ipsen Announces Executive Changes

Ipsen Nominates Peter Guenter to its Board of Directors, Effective January 28, 2026

Ipsen Announces Executive Changes

Ipsen Announces Demise of Board Member Henri Beaufour on November 28, 2025

Recent updates

Ipsen S.A. (ENXTPA:IPN) completed the acquisition of Kartos Therapeutics, Inc.

Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026

Ipsen Provides Update On Phase III BOLD Trial In Biliary Atresia

Ipsen Reports Positive Topline Phase III Results for Dysport in Both Episodic and Chronic Migraine

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Kartos Therapeutics, Inc. for $1.8 billion.

Ipsen Presents New Late-Breaking Results and Real-World Evidence for IQIRVO in Primary Biliary Cholangitis

Ipsen Announces Late-Breaking Data from First Head-To-Head Study Comparing Dysport and Botox in Adults with Upper Limb Spasticity

Ipsen Presents First-In-Class Phase II Corabotase Data In Glabellar Lines

Ipsen Unveils Corabotase, First-In-Class Recombinant Neuroinhibitor RNI

Ipsen S.A. Confirms Financial Guidance for the Full-Year 2026

Ipsen Receives European Union Approval for Ojemda as Targeted Therapy in Relapsed or Refractory Pediatric Low-Grade Glioma

Ipsen S.A., Annual General Meeting, May 13, 2026

Ipsen Showcases Transformative Potential of Early Immuno-Oncology Pipeline At AACR

Ipsen Announces Executive Changes

Ipsen Voluntarily Withdraws Tazverik in Follicular Lymphoma and Epithelioid Sarcoma

Ipsen S.A. to Report First Half, 2026 Results on Jul 30, 2026

Ipsen S.A. Provides Earnings Guidance for the Full Year 2026

Ipsen Nominates Peter Guenter to its Board of Directors, Effective January 28, 2026

Ipsen Announces Executive Changes

Ipsen Announces the Presentation of 14 Across Multiple Neurological Conditions At the Toxins 2026 Conference in Madrid, Spain

Ipsen Announces Pivotal Phase II FALKON Trial Do Not Meet Its Primary Endpoint of Reducing New Heterotopic Ossification in Adults and Children Living with Fibrodysplasia Ossificans Progressiva

Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others.

Ipsen Announces Demise of Board Member Henri Beaufour on November 28, 2025

Ipsen S.A. to Report Q4, 2025 Results on Feb 12, 2026

Ipsen Announces That Japan's Ministry of Health, Labour and Welfare Grants Regulatory Approval for Bylvay®? (Odevixibat) for the Treatment of Pruritus Associated with Progressive Familial Intrahepatic Cholestasis

Medison and Ipsen Announces Health Canada Approves Bylvay™? (odevixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen S.A. Revises Earnings Guidance for the Year 2025

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for CABOMETYX®? (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Ipsen S.A. Announces New Appointments to Its Executive Committee

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Ipsen Announces New Data from Two Late-Breaking Presentations on IQIRVO®? (elafibranor) During the European Association for the Study of the Liver Congress

Ipsen to Present Data from the Late-Breaking Elafibranor in the Investigational Phase II ELMWOOD Study at the European Association for the Study of the Liver (EASL) Congress

Ipsen S.A. Confirms Guidance for the Full-Year 2025

Ipsen S.A. Provides Earnings Guidance for the Year 2025

Ipsen S.A., Annual General Meeting, May 21, 2025

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. Confirms Sales Guidance for the Fiscal Year 2023

Ipsen S.A., Annual General Meeting, May 28, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

マネジメント基準チェック /24